Trump signs an executive order easing FDA restrictions to speed psychedelic drug research for PTSD treatment

The executive order signed by President Donald Trump aims to expedite research and access to psychedelics that are used outside the US to treat post-traumatic stress disorder (PTSD). Trump said the order would help people with debilitating PTSD symptoms reclaim their lives, after a US regulatory environment that limited research and broader access. The signing occurred during an Oval Office ceremony. The move is positioned as a push to accelerate psychedelic development tied specifically to PTSD care, including reducing friction around FDA restrictions while supporting faster progress toward availability.